Geron Corporation (NASDAQ:GERN) forecasts $220–240 million in RYTELO revenue and $230–240 million in operating expenses for 2026 post-restructuring. The company aims for profitability in the second half of the year by increasing outreach efforts to physicians and patients. GERN prioritizes U.S. commercialization and international expansion, with a focus on its Phase 3 IMpactMF trial. The company presented new IMerge data at the 2025 ASH meeting and secured up to $125 million through July 2026. GERN is trimming its workforce by nearly a third to reduce operating expenses and achieve profitability by the end of 2026.

Read more at Yahoo Finance: Geron Corporation (GERN) Eyes Profitability in 2026 amid Restructuring Drive